| prov:value
| - tient populations, involving 21,105 and 8,292 patients, respectively.1,2 The submission of our MAA in Europe for edoxaban represents our long standing commitment to addressing the needs of patients living with cardiovascular diseases, including AF or VTE, said Glenn Gormley, MD, PhD, Senior Exe
|